Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Schwind

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
Leukemia|December 12, 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapySusan P Whitman, Jessica Kohlschmidt, Kati Maharry, et al.
Blood|October 28, 2011
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryKlaus H Metzeler, Heiko Becker, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaGuido Marcucci, Klaus H Metzeler, Sebastian Schwind, et al.
Blood|May 6, 2010
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
Blood|May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaWilliam Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
Blood|September 16, 2010
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Guido Marcucci, Kati Maharry, et al.
Transfusion|July 29, 2025
Impact of cellular composition and T-cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T-cellsVladan Vučinić, Theresa Tumewu, Mandy Brückner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signaturesJason H Mendler, Kati Maharry, Michael D Radmacher, et al.
Leukemia|October 7, 2018
Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRAChristopher J Walker, Christopher C Oakes, Luke K Genutis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemiaKrzysztof Mrózek, Guido Marcucci, Deedra Nicolet, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
Leukemia|December 12, 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapySusan P Whitman, Jessica Kohlschmidt, Kati Maharry, et al.
Blood|October 28, 2011
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryKlaus H Metzeler, Heiko Becker, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaGuido Marcucci, Klaus H Metzeler, Sebastian Schwind, et al.
Blood|May 6, 2010
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
Blood|May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaWilliam Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
Blood|September 16, 2010
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Guido Marcucci, Kati Maharry, et al.
Transfusion|July 29, 2025
Impact of cellular composition and T-cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T-cellsVladan Vučinić, Theresa Tumewu, Mandy Brückner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signaturesJason H Mendler, Kati Maharry, Michael D Radmacher, et al.
Leukemia|October 7, 2018
Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRAChristopher J Walker, Christopher C Oakes, Luke K Genutis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemiaKrzysztof Mrózek, Guido Marcucci, Deedra Nicolet, et al.
Pageof 11